SoniVie's lead product, TIVUS, is an investigational intravascular treatment that can be performed as part of a routine right heart catheterization for patients suffering from pulmonary arterial hypertension (PAH)
Location: Israel, Center District, Drom HaSharon Regional Council
Total raised: $60M
Founded date: 2009
Investors 4
| Date | Name | Website |
| - | TechWald H... | techwald.c... |
| 30.01.2023 | Omega Fund... | omegafunds... |
| 12.01.2023 | Andera Par... | anderapart... |
| - | HealthTech... | healthtech... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.01.2023 | Series C | $60M | Andera Par... |
Mentions in press and media 14
| Date | Title | Description |
| 03.03.2025 | Boston Scientific announces agreement to acquire SoniVie Ltd. | Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire SoniVie Ltd., a privately held medical device company that has developed the TIVUS™ Intravascular Ultrasound System. An investig... |
| 18.11.2024 | The Future of Medtech: Leadership Changes and Data-Driven Innovations | The medical technology landscape is evolving rapidly. New leaders are stepping in, and data is becoming the lifeblood of innovation. This is a time of transformation, where the right leadership can steer companies toward success, and data c... |
| 18.11.2024 | SoniVie Ltd., Appoints Veteran Medtech Executive Raymond W. Cohen as Chairman of its Board of Directors | TEL AVIV, Israel, Nov. 18, 2024 /PRNewswire/ -- SoniVie Ltd., a medical device company developing a proprietary renal denervation system to treat hypertension, announced today the appointment of Raymond W. Cohen to serve as its chairman of ... |
| 26.07.2024 | Andera Partners Co-Leads $196 Million Round for Kestra Medical and Welcomes Raymond W. Cohen to Board of Directors | Kestra Medical is an American company also present in Ireland, which has developed and commercializes a medical device: a vest equipped with a portable defibrillator for patients at risk of sudden cardiac arrest. The $196 million financing ... |
| 24.07.2024 | SoniVie announces advancements in its renal denervation program: REDUCED-1 pilot study results, radial access First-In-Human results, and FDA pivotal IDE approval of The THRIVE global study | SoniVie announces RDN pilot results, radial access FIH and FDA pivotal IDE approval, initiating the global THRIVE study in US, Europe and Israel TEL AVIV, Israel, July 24, 2024 /PRNewswire/ -- SoniVie, which has developed a novel proprietar... |
| 01.02.2024 | SoniVie announces enrollment completion in the REDUCED-1 pilot study with TIVUS™ Ultra-Sound Renal Denervation | SoniVie announces enrollment completion in the REDUCED-1 pilot study TEL AVIV, Israel, Feb. 1, 2024 /PRNewswire/ -- SoniVie, an Israeli company developing a novel, proprietary Therapeutic Intra-Vascular Ultrasound (TIVUSTM) System to treat ... |
| 12.01.2023 | Andera Partners backs $60 million series C for hypertension medtech SoniVie | SoniVie, an Italy and Israel-run med tech seeking to treat hypertension through the use of ultrasound, has closed a $60 million series C round to make headway toward its clinical and regulatory pipeline. Paris-based Andera Partners led the ... |
| 09.01.2023 | SoniVie Raises $60M in Series C Financing | SoniVie, a Tel Aviv, Israel-based medical device company, raised $60M in Series C funding. The round was led by Andera Partners, with participation from Supernova Invest, Omega Funds and TechWald. The company intends to use the funds to sup... |
| 09.01.2023 | SoniVie Raises $60m in Round C Financing, and Appoints New Board Members | The funds, provided by new investors and current shareholder, will be used to support the Company clinical and regulatory path towards pre-market approval of its TIVUS™ technology for the treatment of hypertension TEL AVIV, Israel, Jan. 9, ... |
| 13.07.2022 | SoniVie Announces successful procedure with TIVUS system on first patient enrolled for REDUCED1 Pilot study | TEL AVIV, Israel, July 13, 2022 /PRNewswire/ -- SoniVie, an Israeli company developing a novel proprietary Therapeutic Intra-Vascular Ultrasound (TIVUS™) System to treat a variety of hypertensive disorders, announced that on May 30th 2022 t... |
Show more